Agenus Inc. Dividends Paid (Total)

Dividends Paid (Total) of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Dividends Paid (Total) growth rates and interactive chart.

Highlights and Quick Summary

  • Dividends Paid (Total) for the quarter ending December 30, 2014 was $0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Dividends Paid (Total) decreased by -100.0%
  • Annual Dividends Paid (Total) for 2014 was $-461 Thousand (a -22.25% decrease from previous year)
  • Annual Dividends Paid (Total) for 2012 was $-593 Thousand (a -25.0% decrease from previous year)
  • Annual Dividends Paid (Total) for 2011 was $-791 Thousand (a -0.0% decrease from previous year)
  • Twelve month Dividends Paid (Total) ending December 30, 2014 was $-659 Thousand (a -23.09% decrease compared to previous quarter)
  • Twelve month trailing Dividends Paid (Total) decreased by -16.69% year-over-year
Trailing Dividends Paid (Total) for the last four month:
30 Dec '14 29 Sep '14 30 Dec '12 29 Sep '12
$-659 Thousand $-856 Thousand $-593 Thousand $-791 Thousand
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Dividends Paid (Total) of Agenus Inc.

Most recent Dividends Paid (Total)of AGEN including historical data for past 10 years.

Interactive Chart of Dividends Paid (Total) of Agenus Inc.

Agenus Inc. Dividends Paid (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2014 $0.0 $-0.46 $-0.46
2012 $0.0 $-0.2 $-0.2 $-0.2 $-0.59
2011 $-0.2 $-0.2 $-0.2 $-0.2 $-0.79
2010 $-0.2 $-0.2 $-0.2 $-0.2 $-0.79
2009 $-0.2 $-0.2 $-0.79

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.